Ultragenyx Pharmaceutical RARE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's additional paid-in capital?
- Ultragenyx Pharmaceutical (RARE) reported additional paid-in capital of $4.48B in Q1 2026.
- How has Ultragenyx Pharmaceutical's additional paid-in capital changed year-over-year?
- Ultragenyx Pharmaceutical's additional paid-in capital increased by 5.4% year-over-year, from $4.25B to $4.48B.
- What is the long-term trend for Ultragenyx Pharmaceutical's additional paid-in capital?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's additional paid-in capital has grown at a 9.9% compound annual growth rate (CAGR), from $2.77B to $4.45B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.